Search the Newsreel

Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A

An amended Schedule 13G filing for Tango Therapeutics (TNGX) reveals that Nextech Crossover I SCSp, Nextech Crossover I GP S.a r.l., and individuals Ian Charoub, Costas Constantinides, and Rocco Sgobbo now report 0 beneficial shares, equating to 0.0% ownership as of June 30, 2026. …

Contango Silver & Gold (NYSE: CTGO) swings to Q2 operating loss but boosts cash, reshapes hedges

Contango Silver & Gold Inc. (TSX: CTGO) Stock Price, News & Analysis

Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a 6.0% beneficial ownership stake in Tango Therapeutics, Inc. (TNGX) through a Schedule 13G filing. This holding amounts to 9,742,402.80 shares and signifies shared voting and dispositive power over …

Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants

Farallon Capital Management, L.L.C. and its affiliated funds have disclosed a beneficial ownership of 16,270,187 shares of Tango Therapeutics (TNGX), representing 9.8% of the company's outstanding common stock. This includes 12,277,000 directly held shares and 3,993,187 pre-funded common stock purchase warrants, which are exercisable …

MANGOCEUTICALS, INC. Q2 2026: Revenue $68.76K, EPS $(0.09) — 10-Q Summary

MANGOCEUTICALS, INC. reported Q2 2026 results with revenue of $68,757 and a net loss of $(1,606,653), translating to a diluted EPS of $(0.09). Revenue declined year-over-year by 59.1% as the company focused on strategic shifts towards telehealth platform growth and in-house e-commerce, but net …

Mangoceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Mangoceuticals, Inc. announced its earnings for the second quarter and six months ending June 30, 2026. For the second quarter, sales were USD 0.068757 million with a net loss of USD 1.31 million. Over the six-month period, sales totaled USD 0.136621 million, resulting in …

Nuclea’s planned Moltex deal could add 80 nuclear patents

Mangoceuticals' merger partner, Nuclea Energy, Inc., has entered into a definitive agreement to acquire advanced nuclear technology assets from Moltex Energy, which is currently in administration. The acquisition includes intellectual property for Moltex’s SSR‑W advanced molten salt reactor, WATSS spent-fuel recycling process, and the …

Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX

Handelsbanken Fonder AB has acquired 287,900 shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) for approximately $9 million, establishing a 0.20% stake in the company. Institutional investors now collectively own nearly 79% of Tango Therapeutics, a clinical-stage biotechnology company focused on precision cancer medicines. The company …

Tango Therapeutics (TNGX) Is Getting Fresh Attention, What Are Investors Looking At?

Tango Therapeutics (TNGX) recently saw investor attention due to a wider Q2 net loss, the cessation of collaboration revenue, and a new US$400 million at-the-market equity offering which could dilute shareholders. Despite short-term share price drops, the stock shows strong momentum over longer periods, …

Mangoceuticals (MGRX) Q2 2026 loss shrinks while cash and revenue fall

Contango Silver & Gold Inc. Q2 2026: Revenue $125M, EPS $0.14— 10-Q Summary

Contango Silver & Gold (CTGO) expands portfolio with $264M Dolly Varden acquisition

Contango Silver & Gold Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside

Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets

Mangoceuticals Inc.'s merger partner, Nuclea Energy, Inc., has entered into a definitive agreement to acquire advanced nuclear technology assets from Moltex Energy Limited. This acquisition includes Moltex's Stable Salt Reactor–Wasteburner (SSR-W) and Waste To Stable Salt (WATSS) spent nuclear fuel recycling process, along with …

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for AngioDynamics (ANGO). Shares have added about 8.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings …

Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX

Tema ETFs LLC has acquired a new stake of 55,384 shares in Tango Therapeutics, Inc. (NASDAQ:TNGX), valued at approximately $1.73 million. Other institutional investors have also adjusted their holdings, and company insider Adam Crystal sold 27,000 shares. Despite missing EPS estimates, analysts maintain a …

FingerTango Schedules Board Meeting to Review 2026 Interim Results and Dividend

Tango Therapeutics Inc (TNGX) News, Articles, Events & Latest Updates

Adage Capital discloses 3.44% Tango Therapeutics (TNGX) stake in 13G/A filing

Adage Capital Management, L.P. and associated parties have disclosed a 3.44% beneficial ownership stake in Tango Therapeutics, Inc. (TNGX) through a Schedule 13G/A filing. This ownership amounts to 5,600,000 shares, with both shared voting and shared dispositive power. The percentage is calculated based on …

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses

Tango Therapeutics (TNGX) reported a wider-than-expected loss of 37 cents per share in Q2 2026, missing the Zacks Consensus Estimate of 31 cents, primarily due to higher operating expenses and no collaboration revenues. Despite the earnings miss causing a 4.8% stock dip, TNGX shares …

Guggenheim raises Tango Therapeutics stock price target to $35

Guggenheim raised its price target for Tango Therapeutics Inc. (NASDAQ:TNGX) to $35 from $32, maintaining a Buy rating, following the company's Q2 2026 results and plans for a Phase 3 trial. Despite the stock's significant increase over the past year, InvestingPro suggests it is …

What's Going On With Contango Silver & Gold Inc. Stock Wednesday?

Tango Therapeutics (TNGX) Stock Faces Cash Burn Pressure After Revenue Vanishes

Tango Therapeutics (TNGX) saw its stock drop by about 5% after reporting a widened net loss of US$100.9m and zero revenue for the first half of 2026, compared to US$8.6m in the prior year. Despite a significant equity raise earlier in the year, the …

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

Key Points Interested in AngioDynamics, Inc.? Here are five stocks we like better. MedTech is expected to become AngioDynamics' majority revenue source in fiscal 2027, rising from 47% of fiscal 2026 revenue. Management forecasts 12%–15% MedTech growth, driven by Auryon, mechanical thrombectomy products and …

Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $44.58, Implies 61% Upside

Analysts have increased the average 12-month price target for Tango Therapeutics, Inc. (TNGX) stock from $44.33 to $44.58, with a range of $24 to $69 per share. This updated target suggests a 61% potential upside based on the Aug. 10 closing price. The consensus …

AngioDynamics at Canaccord Genuity conference: growth pivot deepens

AngioDynamics discussed its strategic pivot from a legacy catheter business to a high-growth MedTech portfolio at the Canaccord Genuity conference. The company highlighted 18% MedTech revenue growth in fiscal 2026, now comprising 47% of total revenue, and projected 12-15% MedTech growth for fiscal 2027. …

AngioDynamics, Inc. (ANGO) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

AngioDynamics, Inc. (ANGO) presented a slideshow at Canaccord Genuity's 46th Annual Growth Conference. The article, authored by SA Transcripts, highlights the company's participation in this event. SA Transcripts is responsible for publishing thousands of quarterly earnings call transcripts and other transcript-related projects on Seeking …

AngioDynamics Port Catheter Lawsuit

Wisner Baum is actively investigating claims against AngioDynamics and Navilyst Medical concerning implantable port catheters due to reported complications like infection, thrombosis, device fracture, and migration. The AngioDynamics Port Catheter MDL, centralized in California, has grown to over 400 pending actions as of July …

Why is Tango Therapeutics stock sliding today?

Tango Therapeutics (TNGX) stock fell nearly 4.0% after the company reported Q2 2026 financial results that missed Wall Street expectations, with a wider net loss per share and zero revenue. Operating costs, particularly general and administrative expenses, nearly doubled year-over-year. Despite progress in clinical …

Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results

Tango Therapeutics faces earnings test as PRMT5 data fuels rally

Tango Therapeutics (TNGX) is set to report its second-quarter results, with investors closely watching for updates on its PRMT5 inhibitor programs and its path to a pivotal pancreatic cancer trial. The company's stock has rallied significantly due to promising combination data, and analysts are …